Ellen A. Goldmuntz

Pediatric Rheumatology

6610 Rockledge Dr Ste 3025
Bethesda, MD 20817

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trial.

Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trial.

Journal: JCI insight

Published: November 25, 2025

Six-Month Outcomes in Children With COVID-19 or Multisystem Inflammatory Syndrome in Children.

Six-Month Outcomes in Children With COVID-19 or Multisystem Inflammatory Syndrome in Children.

Journal: Hospital pediatrics

Published: July 07, 2025

Six-Month Outcomes in Children With COVID-19 or Multisystem Inflammatory Syndrome in Children.

Six-Month Outcomes in Children With COVID-19 or Multisystem Inflammatory Syndrome in Children.

Journal: Hospital pediatrics

Published: July 07, 2025

A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis.

A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: June 05, 2025

A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis.

A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: June 05, 2025

Prospective SARS-CoV-2 Booster Vaccination in Immunosuppressant-Treated Systemic Autoimmune Disease Patients in a Randomized Controlled Trial.

Prospective SARS-CoV-2 Booster Vaccination in Immunosuppressant-Treated Systemic Autoimmune Disease Patients in a Randomized Controlled Trial.

Journal: medRxiv : the preprint server for health sciences

Published: April 08, 2025

25 Years of Biologics for the Treatment of Pediatric Rheumatic Disease: Advances in Prognosis and Ongoing Challenges.

25 Years of Biologics for the Treatment of Pediatric Rheumatic Disease: Advances in Prognosis and Ongoing Challenges.

Journal: Arthritis care & research

Published: July 22, 2024

Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial.

Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial.

Journal: The Lancet. Rheumatology

Published: July 31, 2023

Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long-Term Normalization of Systemic Sclerosis Molecular Signatures.

Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long-Term Normalization of Systemic Sclerosis Molecular Signatures.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: June 07, 2023

Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis.

Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis.

Journal: Annals of the rheumatic diseases

Published: May 08, 2022

Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation.

Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation.

Journal: Annals of the rheumatic diseases

Published: December 06, 2021

Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy.

Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy.

Journal: Rheumatology (Oxford, England)

Published: October 06, 2021

Showing 1-12 of 29

Last Updated: 09/26/2026